BC Extra | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

Four biotechs set terms for U.S. IPOs Monday in a month that has already seen five go public, including the largest raise of the year. Collectively, the quartet could raise over $500 million. ADC Therapeutics...
BC Extra | Sep 10, 2019
Financial News

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

Qiming leads Insilico’s $37M B round  Insilico Medicine Inc. (Hong Kong, China) raised $37 million in a series B round led by Qiming Venture Partners. Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu...
BC Week In Review | Dec 7, 2018
Clinical News

Aprea's MDS candidate leads to 95% ORR in Phase Ib/II

Aprea Therapeutics AB (Stockholm, Sweden) reported data from 20 evaluable patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) in a Phase Ib/II trial showing that APR-246 plus Vidaza azacitidine led to an overall...
BC Week In Review | Dec 7, 2018
Financial News

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round on Nov. 30, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic...
BC Extra | Nov 30, 2018
Financial News

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic syndrome (MDS). The...
BC Week In Review | Apr 27, 2018
Clinical News

Aprea reports Phase Ib/II response data for APR-246 in MDS

Aprea Therapeutics AB (Stockholm, Sweden) said APR-246 plus Vidaza azacitidine led to an overall response rate (ORR) of 100%, including six complete responses and two marrow complete responses, in eight evaluable patients with myelodysplastic syndrome...
BC Innovations | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
BC Week In Review | May 25, 2017
Clinical News

Aprea starts Phase Ib/II of APR-246 for MDS

Aprea Therapeutics AB (Solna, Sweden) began an open-label, U.S. Phase Ib/II trial to evaluate APR-246 in about 60 patients with tumor protein p53 ( TP53 ; p53) mutant myelodysplastic syndrome (MDS). The dose-escalation Phase I part...
BC Innovations | Apr 13, 2017
Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53 -mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines,...
BC Innovations | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

After decades of research and countless failed attempts at drug development, industry is reviving its interest in two of oncology’s most intractable targets, p53 and Ras. While no one denies there’s still a long road...
Items per page:
1 - 10 of 26